Calidi Biotherapeutics Inc

NYSE American:CLDIUnited States

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.

Contact Information

Headquarters

4475 Executive Drive, Suite 200SAN DIEGO, CA, United States 92121

Phone

858-794-9600

Fax

858-794-9605

Executives

Chairman of the Board, Chief Executive Officer

Allan Camaisa

Chief Financial Officer

Andrew Jackson

President of Medical and Scientific Affairs, Interim Chief Medical Officer

Boris Minev

Chief Legal Officer, Chief Diversity Officer

Wendy Pizarro Campbell

Independent Director

Scott Leftwich